Acute Invasive Aspergillosis Treatment Market, Acute Invasive Aspergillosis Mark
Posted by Pareesh on July 2nd, 2018
Acute Invasive Aspergillosis is an acute infection or fungal growth, which arises due to Aspergillus fungus. Almost everyone comes in contact with the Aspergillus fungus as it is found on decaying vegetation and dead leaves, however, not everyone is susceptible to the infection. Aspergillosis is categorized into various types such as invasive aspergillosis, chronic pulmonary aspergillosis, allergic bronchopulmonary aspergillosis, allergic aspergillus sinusitis, aspergilloma, and cutaneous aspergillosis. Active invasive aspergillosis (IA) is a rare, opportunistic, and serious fungal infection, which affects immunocompromised patients or those suffering from lung diseases. Risk factors responsible for the development of invasive aspergillosis infection include weakened immune system, low white blood cell count, presence of lung cavities, asthma or cystic fibrosis, and long-term corticosteroid therapy. Commercially available drugs for the treatment of aspergillus infection include Voriconazole, Capsofungin, and Amphotericin B, among others.
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1520
Acute Invasive Aspergillosis Treatment Market Drivers
According to the Centers for Disease Control and Prevention, the epidemiology of invasive aspergillus infection is dependent upon increasing number of solid organ transplants, stem cell transplant, and newer immunosuppressive agents, 2017. According to Organ Procurement and Transplantation Network (OPTN), around 8,500 organ transplants have been performed in 2018 and the number is expected to grow in the near future. These factors are expected to support the growth of the acute invasive aspergillosis treatment market. Patients who undergo organ transplant procedure are often prescribed immunosuppressant medications, which increases their susceptibility to aspergillosis infection. Similarly, patients in the advanced stages of AIDS are also highly susceptible to opportunistic infections such as aspergillosis. According to the World Health Organization (WHO), around 36.7 million people were found suffering from HIV in 2016. Extended use of corticosteroids further weakens the immune system, thus increasing the risk of developing such infections.
The U.S. Food & Drug Administration (FDA) is increasingly approving several drugs for the treatment of this infection. For instance, Isavuconazonium, a prodrug form of Isavuconazole was approved by the FDA in 2015. Astellas Pharma US, Inc. markets Isavuconazonium under the brand name Cresemba. Astellas Pharma partnered with Basilea Pharmaceutica International Ltd. for license, co-development, and co-promotion of Isavuconazole (Cresemba), in 2010. In 2014, Basilea Pharmaceutica International Ltd.
Request TOC of the Report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1520
Acute Invasive Aspergillosis Treatment Market Insights
Most antifungal medications have lost their patent protection over the last few years and generic versions of these products are increasingly being made available by generic drug manufacturers, which in turn is supporting growth of the acute invasive aspergillosis treatment market. Manufacturers such as Amneal Pharmaceuticals, Sandoz Inc., Glenmark Pharmaceuticals Ltd., Mylan Pharmaceuticals, Inc., and Teva Pharmaceuticals offer generic versions of antifungal medications in the acute invasive aspergillosis treatment market. Independent organizations are dedicated towards research and development of novel antifungal therapies. For instance, F2G, an established U.K.-based biotechnology company is focused on the discovery and development of novel drugs for the treatment of serious fungal diseases such as acute invasive aspergillosis.
Key players operating in the global acute invasive aspergillosis treatment market include GlaxoSmithKline, Mylan Pharmaceuticals, Inc., Novartis AG, Abbott laboratories, Eli Lilly and Company, AstraZeneca Plc, Pfizer, Inc., Johnson & Johnson, Takeda Pharmaceutical Company Ltd., Astellas, and Basilea Pharmaceutica International Ltd.
Acute Invasive Aspergillosis Treatment Market Taxonomy-
Global acute invasive aspergillosis treatment market is segmented on the basis of drug type, distribution channel, and geography. By Drug Type- Antifungal, Voriconazole, Capsofungin, Itraconazole, Isavuconazole, Amphotericin B, Others, Corticosteroids, Prednisolone, Prednisone, Methylprednisolone,. By Distribution Channel- Hospital Pharmacies, Online Pharmacies, Retail Pharmacies,. By Geography- North America, Europe, Asia Pacific, Latin America, Middle East, Africa,.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Like it? Share it!
About the AuthorPareesh
Joined: May 31st, 2017
Articles Posted: 1,431
More by this author